Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia

Journal of Clinical Oncology

Volumn 27, Issue 17, 2009, Pages 2838-2847

  Ludwig, Heinz ^a   Crawford, Jeffrey ^a   Österborg, Anders ^a   Vansteenkiste, Johan ^a   Henry, David H ^a   Fleishman, Alex ^a   Bridges, Ken ^a   Glaspy, John A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; DRUG DERIVATIVE; ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BREAST TUMOR; CANCER STAGING; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; FEMALE GENITAL TRACT TUMOR; FOLLOW UP; GASTROINTESTINAL TUMOR; HEART ARRHYTHMIA; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LUNG SMALL CELL CANCER; LUNG TUMOR; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEIZURE; SOLID TUMOR; THROMBOEMBOLISM; TREATMENT DURATION; UROGENITAL TRACT TUMOR; BLOOD AUTOTRANSFUSION; DISEASE FREE SURVIVAL; DRUG THERAPY; DRUG TOXICITY; META ANALYSIS; METABOLISM; TREATMENT OUTCOME;

ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION, AUTOLOGOUS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG THERAPY; DRUG TOXICITY; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; TREATMENT OUTCOME;

EID: 67649934442     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.1130     Document Type: Article

References (41)

1. Demetri GD, Kris M, Wade J, et al: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study - Procrit Study Group. J Clin Oncol 16:3412-3425, 1998
2. Glaspy J: The impact of epoetin alfa on quality of life during cancer chemotherapy: A fresh look at an old problem. Semin Hematol 34:20-26, 1997
3. Gabrilove JL, Cleeland CS, Livingston RB, et al: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882, 2001
4. Littlewood TJ, Bajetta E, Nortier JW, et al: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874, 2001
5. Vansteenkiste J, Pirker R, Massuti B, et al: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94:1211-1220, 2002
6. Osterborg A, Brandberg Y, Molostova V, et al: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 20:2486-2494, 2002
7. Taylor K, Ganly P, Charu V, et al: Randomized, double-blind, placebo-controlled study of darbepoetin alfa every 3 weeks for the treatment of chemotherapy-induced anemia. Blood 106, 2005 (abstr 3556)
8. Grote T, Yeilding AL, Castillo R, et al: Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 23:9377-9386, 2005
9. Witzig TE, Silberstein PT, Loprinzi CL, et al: Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606-2617, 2005
10. Kotasek D, Steger G, Faught W, et al: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy: Results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39:2026-2034, 2003
11. Moebus V, Lueck H, Thomssen C, et al: The impact of epoetin-alpha on anemia, red blood cell (RBC) transfusions, and survival in breast cancer patients (pts) treated with dose-dense sequential chemotherapy: Mature results of an AGO phase III study (ETC trial). J Clin Oncol 25:20s, 2007 (suppl; abstr 569)
12. Pirker R, Ramlau R, Schuette W, et al: A phase 3 randomized, double blind, placebo-controlled study of patients with previously untreated extensive-stage small cell lung cancer (SCLC) treated with platinum plus etoposide chemotherapy with or without darbepoetin alfa. J Thorac Oncol 2, 2007 (abstr PD6-3-6)
13. Bohlius J, Wilson J, Seidenfeld J, et al: Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98:708-714, 2006
14. Seidenfeld J, Pipe M, JB, et al: Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment: Comparative Effectiveness Review no. 3. Prepared by Blue Cross and Blue Shield Association Evaluation Center Evidence-based Practice Center under contract no. 290-02-0026. Rockville, MD, Agency for Healthcare Research and Quality, 2006. www.effectivehealthcare.arhq.gov/reports/final.cfm
15. Ross SD, Allen IE, Henry DH, et al: Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clin Ther 28:801-831, 2006
16. Aapro M, Coiffier B, Dunst J, et al: Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis. Br J Cancer 95:1467-1473, 2006
17. Smith RE Jr, Aapro MS, Ludwig H, et al: Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26:1040-1050, 2008
18. Henke M, Laszig R, Rube C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362:1255-1260, 2003
19. Leyland-Jones B, Semiglazov V, Pawlicki M, et al: Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23:5960-5972, 2005
20. Wright JR, Ung YC, Julian JA, et al: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027-1032, 2007
21. Overgaard J, Hoff CM, Sand Hansen H, et al: Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp® ) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): The Danish Head and Neck Cancer Group (DAH-ANCA 10) randomized trial. Presented at 14th European Cancer Conference, Barcelona, Spain, September 23-27, 2007 (abstr 6LB)
22. Hedenus M, Adriansson M, San Miguel J, et al: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 122:394-403, 2003
23. Amgen: Update to Hedenus et al (2003), in Safety of Erythropoiesis- Stimulating Agents (ESAs) in Oncology: Background Information for Oncologic Drugs Advisory Committee. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4301b2-01-01-Amgen.pdf
24. Thomas G, Ali S, Hoebers FJ, et al: Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 108:317-325, 2008
25. Amgen: Amgen announces interim results of Aranesp "PREPARE" study in breast cancer patients [Amgen press release]: November 30, 2007. Http://wwwext.amgen.com/ media / media-pr-detail . jsp?year=2007&releaseID- 1083091
26. Azria D, Zouhair A, Serre A, et al: [Anemia in head and neck cancers]. Bull Cancer 92:445-451, 2005
27. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924, 2008
28. Amgen Inc: Aranesp® (Darbepoetin alfa) Package Insert. Thousand Oaks, CA, Amgen, 2008
29. Ortho Biotech Products: L.P. PROCRIT® (Epoetin alfa) package insert. Raritan, NJ, Ortho Biotech, 2008
30. Kotasek D, Albertsson M, Mackey J, et al: Once per cycle dosing of darbepoetin alfa is feasible in anemic cancer patients receiving chemotherapy. Ann Oncol 13, 2002 (abstr 626PD)
31. Hedenus M, Hansen S, Taylor K, et al: Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies. Br J Haematol 119:79-86, 2002
32. Rizzo JD, Somerfield MR, Hagerty KL, et al: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/ American Society of Hematology clinical practice guideline update. J Clin Oncol 26:132-149, 2008
33. Rodgers GM: NCCN Practice Guidelines in Oncology: Cancer and treatment-related anemia, National Comprehensive Cancer Network. Http://www.nccn.org/professionals/physician-gls/PDF/anemia.pdf
34. Bohlius J, Brillant C, Clarke M, et al: Recombinant human erythropoiesis stimulating agents in cancer patients: Individual patient data metaanalysis on behalf of the EPO IPD Meta-Analysis Collaborative Group. Blood 112, 2008 (abstr 6)
35. Amato A, Pescatori M: Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database Syst Rev 1:CD005033, 2006
36. Heit JA, Silverstein MD, Mohr DN, et al: Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 160:809-815, 2000
37. Blom JW, Doggen CJ, Osanto S, et al: Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715-722, 2005
38. Lyman GH, Glaspy J: Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer 106:223-233, 2006
39. Goodnough LT: Risks of blood transfusion. Crit Care Med 31:S678-S686, 2003
40. Madjdpour C, Spahn DR: Allogeneic red blood cell transfusions: Efficacy, risks, alternatives and indications. Br J Anaesth 95:33-42, 2005
41. Spiess BD: Red cell transfusions and guidelines: A work in progress. Hematol Oncol Clin North Am 21:185-200, 2007